GlassScriptPhysician profile
Benjamin C Truitt
NPI 1669106027
$812.26
in general payments reported to CMS, 2019-2025
13 companies · $659 in 2025
The $659 reported for 2025 was more than what 76% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $153 · 2025: $659.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $812.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $812.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $176.20 | 2025 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $84.62 | 2024-2025 | Camzyos, Eliquis |
| Novartis Pharmaceuticals Corporation | $76.93 | 2024-2025 | |
| Novo Nordisk INC | $74.46 | 2025 | Ozempic |
| Pfizer INC. | $74.23 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $72.94 | 2024-2025 | |
| Edwards Lifesciences Corporation | $51.57 | 2025 | Sapien 3 Ultra Resilia |
| Actelion Pharmaceuticals US, INC. | $49.87 | 2025 | Uptravi, Opsumit |
| Amgen INC. | $46.92 | 2024-2025 | Repatha, Repatha |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $38.50 | 2025 | Lifevest |
| Merck Sharp & Dohme LLC | $30.08 | 2024 | Verquvo |
| Kiniksa Pharmaceuticals International, Plc | $18.31 | 2024 | Arcalyst |
| Astrazeneca Pharmaceuticals LP | $17.63 | 2025 | Brilinta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Truitt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.